Clinical Trial Update: A Prospective, Open Label Study of CERtican in KIdney Transplantation [Phase 4]

View source ↗

Summary

A prospective, open-label Phase 4 study of CERtican in kidney transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Certican (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Transplant | Phase 4 | Status: COMPLETED